Is sentinel lymph node biopsy a viable alternative to complete axillary dissection following neoadjuvant chemotherapy in women with node-positive breast cancer at diagnosis? An updated meta-analysis involving 3,398 patients

American Journal of Surgery

Volumn 212, Issue 5, 2016, Pages 969-981

  El Hage Chehade, Hiba ^a   Headon, Hannah ^a   El Tokhy, Omar ^a   Heeney, Jennifer ^a   Kasem, Abdul ^a   Mokbel, Kefah ^a  

^a Princess Grace Hospital   (United Kingdom)

Author keywords

Breast cancer; Neoadjuvant chemotherapy; Node positive; Sentinel lymph node biopsy

Indexed keywords

ANTINEOPLASTIC AGENT; EPIDERMAL GROWTH FACTOR RECEPTOR 2;

AXILLARY LYMPH NODE; BREAST CANCER; CANCER ADJUVANT THERAPY; FALSE NEGATIVE RESULT; HUMAN; META ANALYSIS; PRIORITY JOURNAL; REVIEW; SENTINEL LYMPH NODE; SENTINEL LYMPH NODE BIOPSY; TREATMENT RESPONSE; TRIPLE NEGATIVE BREAST CANCER; ADULT; AGED; AXILLA; BREAST NEOPLASMS; CANCER STAGING; COMPARATIVE STUDY; FEMALE; LYMPH NODE; LYMPH NODE DISSECTION; MASTECTOMY; MIDDLE AGED; MORTALITY; NEOADJUVANT THERAPY; PATHOLOGY; PROCEDURES; PROGNOSIS; RISK ASSESSMENT; STATISTICS AND NUMERICAL DATA; SURGERY; SURVIVAL ANALYSIS; TUMOR INVASION;

ADULT; AGED; AXILLA; BREAST NEOPLASMS; FALSE NEGATIVE REACTIONS; FEMALE; HUMANS; LYMPH NODE EXCISION; LYMPH NODES; MASTECTOMY; MIDDLE AGED; NEOADJUVANT THERAPY; NEOPLASM INVASIVENESS; NEOPLASM STAGING; PROGNOSIS; RISK ASSESSMENT; SENTINEL LYMPH NODE; SENTINEL LYMPH NODE BIOPSY; SURVIVAL ANALYSIS;

EID: 84992536220     PISSN: 00029610     EISSN: 18791883     Source Type: Journal    
DOI: 10.1016/j.amjsurg.2016.07.018     Document Type: Review

References (88)

1. 1 Hack, T.F., Cohen, L., Katz, J., et al. Physical and psychological morbidity after axillary lymph node dissection for breast cancer. J Clin Oncol 17 (1999), 143–149.
2. 2 Manca, G., Rubello, D., Tardelli, E., et al. Sentinel lymph node biopsy in breast cancer: indications, contraindications, and controversies. Clin Nucl Med 41 (2016), 126–133.
3. 3 Fisher, B., Brown, A., Mamounas, E., et al. Effect of preoperative chemotherapy on local-regional disease in women with operable breast cancer: findings from National Surgical Adjuvant Breast and Bowel Project B-18. J Clin Oncol 15 (1997), 2483–2493.
4. 4 El Hage Chehade, H., Headon, H., Kasem, A., et al. Refining the performance of sentinel lymph node biopsy post-neoadjuvant chemotherapy in patients with pathologically proven pre-treatment node-positive breast Cancer: an update for clinical practice. Anticancer Res 36 (2016), 1461–1471.
5. 5 Shen, J., Gilcrease, M.Z., Babiera, G.V., et al. Feasibility and accuracy of sentinel lymph node biopsy after preoperative chemotherapy in breast cancer patients with documented axillary metastases. Cancer 109 (2007), 1255–1263.
6. 6 Hedges, L.V., Olkin, I., Statistical Methods for Meta-analysis. 1st ed., 1985, Academic Press, Orlando.
7. 7 Higgins, J.P.T., Green, S., (eds.) Cochrane Handbook for Systematic Reviews of Interventions Version 5.1.0 [updated March 2011], 2011, The Cochrane Collaboration Available at: www.cochrane-handbook.org Accessed May 1, 2016.
8. 8 Song, F., Hooper, L., Loke, Y.K., Publication bias: what is it? How do we measure it? How do we avoid it?. Open Access J Clin Trials 5 (2013), 71–81.
9. 9 Duval, S., Tweedie, R., Trim and fill: a simple funnel-plot-based method of testing and adjusting for publication bias in meta-analysis. Biometrics 56 (2000), 455–463.
10. 10 Alvarado, R., Yi, M., Le-Petross, H., et al. The role for sentinel lymph node dissection after neoadjuvant chemotherapy in patients who present with node-positive breast cancer. Ann Surg Oncol 19 (2012), 3177–3184.
11. 11 Boileau, J.F., Poirier, B., Basik, M., et al. Sentinel node biopsy after neoadjuvant chemotherapy in biopsy-proven node-positive breast cancer: the SN FNAC study. J Clin Oncol 33 (2015), 258–264.
12. 12 Boughey, J.C., Suman, V.J., Mittendorf, E.A., et al. Sentinel lymph node surgery after neoadjuvant chemotherapy in patients with node-positive breast cancer: the ACOSOG Z1071 (Alliance) clinical trial. JAMA 310 (2013), 1455–1461.
13. 13 Classe, J.M., Bordes, V., Campion, L., et al. Sentinel lymph node biopsy after neoadjuvant chemotherapy for advanced breast cancer: results of ganglion sentinelle et chimiotherapie neoadjuvante, a French prospective multicentric study. J Clin Oncol 27 (2009), 726–732.
14. 14 Kang, E., Chung, I.Y., Han, S.A., et al. Feasibility of sentinel lymph node biopsy in breast cancer patients with initial axillary lymph node metastasis after primary systemic therapy. J Breast Cancer 14 (2011), 147–152.
15. 15 Kim, J.Y., Kim, M.K., Lee, J.E., et al. Sentinel lymph node biopsy alone after neoadjuvant chemotherapy in patients with initial cytology-proven axillary node metastasis. J Breast Cancer 18 (2015), 22–28.
16. 16 Ozmen, V., Unal, E.S., Muslumanoglu, M.E., et al. Axillary sentinel node biopsy after neoadjuvant chemotherapy. Eur J Surg Oncol 36 (2010), 23–29.
17. 17 Park, S., Park, J.M., Cho, J.H., et al. Sentinel lymph node biopsy after neoadjuvant chemotherapy in patients with cytologically proven node-positive breast cancer at diagnosis. Ann Surg Oncol 20 (2013), 2858–2865.
18. 18 Rebollo-Aguirre, A.C., Gallego-Peinado, M., Sanchez-Sanchez, R., et al. Sentinel lymph node biopsy after neoadjuvant chemotherapy in patients with operable breast cancer and positive axillary nodes at initial diagnosis. Rev Esp Med Nucl Imagen Mol 32 (2013), 240–245.
19. 19 Thomas, S., Prakash, A., Goyal, V., et al. Evaluation of sentinel node biopsy in locally advanced breast cancer patients who become clinically node-negative after neoadjuvant chemotherapy: a preliminary study. Int J Breast Cancer, 2011, 2011, 870263.
20. 20 Yagata, H., Yamauchi, H., Tsugawa, K., et al. Sentinel node biopsy after neoadjuvant chemotherapy in cytologically proven node-positive breast cancer. Clin Breast Cancer 13 (2013), 471–477.
21. 21 Brown, A.S., Hunt, K.K., Shen, J., et al. Histologic changes associated with false-negative sentinel lymph nodes after preoperative chemotherapy in patients with confirmed lymph node-positive breast cancer before treatment. Cancer 116 (2010), 2878–2883.
22. 22 Canavese, G., Dozin, B., Vecchio, C., et al. Accuracy of sentinel lymph node biopsy after neo-adjuvant chemotherapy in patients with locally advanced breast cancer and clinically positive axillary nodes. Eur J Surg Oncol 37 (2011), 688–694.
23. 23 Koslow, S.B., Eisenberg, R.E., Qiu, Q., et al. Sentinel lymph node biopsy is a reliable method for lymph node evaluation in neoadjuvant chemotherapy-treated patients with breast cancer. Am Surg 80 (2014), 171–177.
24. 24 Takei, H., Yoshida, T., Kurosumi, M., et al. Sentinel lymph node biopsy after neoadjuvant chemotherapy predicts pathological axillary lymph node status in breast cancer patients with clinically positive axillary lymph nodes at presentation. Int J Clin Oncol 18 (2013), 547–553.
25. 25 Kuehn, T., Bauerfeind, I., Fehm, T., et al. Sentinel-lymph-node biopsy in patients with breast cancer before and after neoadjuvant chemotherapy (SENTINA): a prospective, multicentre cohort study. Lancet Oncol 14 (2013), 609–618.
26. 26 Lee, W.S., Lee, J.E., Kim, J.H., et al. Analysis of prognostic factors and treatment modality changes in breast Cancer: a single institution study in Korea. Yonsei Med J 48 (2007), 465–473.
27. 27 Rebollo-Aguirre, A.C., Gallego-Peinado, M., Menjon-Beltran, S., et al. Sentinel lymph node biopsy in patients with operable breast cancer treated with neoadjuvant chemotherapy. Rev Esp Med Nucl Imagen Mol 31 (2012), 117–123.
28. 28 Hennessy, B.T., Hortobagyi, G.N., Rouzier, R., et al. Outcome after pathologic complete eradication of cytologically proven breast cancer axillary node metastases following primary chemotherapy. J Clin Oncol 23 (2005), 9304–9311.
29. 29 Fu, J.F., Chen, H.L., Yang, J., et al. Feasibility and accuracy of sentinel lymph node biopsy in clinically node-positive breast cancer after neoadjuvant chemotherapy: a meta-analysis. PLoS One, 9, 2014, e105316.
30. 30 Pesek, S., Ashikaga, T., Krag, L.E., et al. The false-negative rate of sentinel node biopsy in patients with breast cancer: a meta-analysis. World J Surg 36 (2012), 2239–2251.
31. 31 Tan, V.K., Goh, B.K., Fook-Chong, S., et al. The feasibility and accuracy of sentinel lymph node biopsy in clinically node-negative patients after neoadjuvant chemotherapy for breast cancer–a systematic review and meta-analysis. J Surg Oncol 104 (2011), 97–103.
32. 32 Petrelli, F., Lonati, V., Barni, S., Axillary dissection compared to sentinel node biopsy for the treatment of pathologically node-negative breast cancer: a meta-analysis of four randomized trials with long-term follow up. Oncol Rev, 6, 2012, e20.
33. 33 Fisher, E.R., Wang, J., Bryant, J., et al. Pathobiology of preoperative chemotherapy: findings from the National Surgical Adjuvant Breast and Bowel (NSABP) protocol B-18. Cancer 95 (2002), 681–695.
34. 34 Sharkey, F.E., Addington, S.L., Fowler, L.J., et al. Effects of preoperative chemotherapy on the morphology of resectable breast carcinoma. Mod Pathol 9 (1996), 893–900.
35. 35 Boughey, J.C., Suman, V.J., Mittendorf, E.A., et al. Factors affecting sentinel lymph node identification rate after neoadjuvant chemotherapy for breast cancer patients enrolled in ACOSOG Z1071 (Alliance). Ann Surg 261 (2015), 547–552.
36. 36 Boughey, J.C., Ballman, K.V., Le-Petross, H.T., et al. Identification and resection of clipped node decreases the false-negative rate of sentinel lymph node surgery in patients presenting with node-positive breast cancer (T0–T4, N1-N2) who receive neoadjuvant chemotherapy: results from ACOSOG Z1071 (alliance). Ann Surg 263 (2016), 802–807.
37. 37 Caudle, A.S., Yang, W.T., Krishnamurthy, S., et al. Improved axillary evaluation following neoadjuvant therapy for patients with node-positive breast cancer using selective evaluation of clipped nodes: implementation of targeted axillary dissection. J Clin Oncol 34 (2016), 1072–1078.
38. 38 Straver, M.E., Loo, C.E., Alderliesten, T., et al. Marking the axilla with radioactive iodine seeds (MARI procedure) may reduce the need for axillary dissection after neoadjuvant chemotherapy for breast cancer. Br J Surg 97 (2010), 1226–1231.
39. 39 Donker, M., Straver, M.E., Wesseling, J., et al. Marking axillary lymph nodes with radioactive iodine seeds for axillary staging after neoadjuvant systemic treatment in breast cancer patients: the MARI procedure. Ann Surg 261 (2015), 378–382.
40. 40 Martin, R.C. 2nd, Chagpar, A., Scoggins, C.R., et al. Clinicopathologic factors associated with false-negative sentinel lymph-node biopsy in breast cancer. Ann Surg 241 (2005), 1005–1012 discussion 1012–5.
41. 41 Edge, S.B., Compton, C.C., The American Joint Committee on Cancer: the 7th edition of the AJCC cancer staging manual and the future of TNM. Ann Surg Oncol 17 (2010), 1471–1474.
42. 42 Krag, D.N., Anderson, S.J., Julian, T.B., et al. Technical outcomes of sentinel-lymph-node resection and conventional axillary-lymph-node dissection in patients with clinically node-negative breast cancer: results from the NSABP B-32 randomised phase III trial. Lancet Oncol 8 (2007), 881–888.
43. 43 King, T.A., Morrow, M., Surgical issues in patients with breast cancer receiving neoadjuvant chemotherapy. Nat Rev Clin Oncol 12 (2015), 335–343.
44. 44 Giuliano, A.E., McCall, L., Beitsch, P., et al. Locoregional recurrence after sentinel lymph node dissection with or without axillary dissection in patients with sentinel lymph node metastases: the American College of Surgeons Oncology Group Z0011 randomized trial. Ann Surg 252 (2010), 426–432 discussion 432–3.
45. 45 Soerjomataram, I., Louwman, M.W.J., Ribot, J.G., et al. An overview of prognostic factors for long-term survivors of breast cancer. Breast Cancer Res Treat 107 (2008), 309–330.
46. 46 Hunt, K.K., Yi, M., Mittendorf, E.A., et al. Sentinel lymph node surgery after neoadjuvant chemotherapy is accurate and reduces the need for axillary dissection in breast cancer patients. Ann Surg 250 (2009), 558–566.
47. 47 Mougalian, S.S., Hernandez, M., Lei, X., et al. Ten-year outcomes of patients with breast Cancer with cytologically confirmed axillary lymph node metastases and pathologic complete response after primary systemic chemotherapy. JAMA Oncol 2 (2016), 508–516.
48. 48 Spanheimer, P.M., Carr, J.C., Thomas, A., et al. The response to neoadjuvant chemotherapy predicts clinical outcome and increases breast conservation in advanced breast cancer. Am J Surg 206 (2013), 2–7.
49. 49 Cocquyt, V.F., Blondeel, P.N., Depypere, H.T., et al. Different responses to preoperative chemotherapy for invasive lobular and invasive ductal breast carcinoma. Eur J Surg Oncol 29 (2003), 361–367.
50. 50 Cristofanilli, M., Gonzalez-Angulo, A., Sneige, N., et al. Invasive lobular carcinoma classic type: response to primary chemotherapy and survival outcomes. J Clin Oncol 23 (2005), 41–48.
51. 51 Delpech, Y., Coutant, C., Hsu, L., et al. Clinical benefit from neoadjuvant chemotherapy in oestrogen receptor-positive invasive ductal and lobular carcinomas. Br J Cancer 108 (2013), 285–291.
52. 52 Straver, M.E., Rutgers, E.J., Russell, N.S., et al. Towards rational axillary treatment in relation to neoadjuvant therapy in breast cancer. Eur J Cancer 45 (2009), 2284–2292.
53. 53 Schneeweiss, A., Chia, S., Hickish, T., et al. Pertuzumab plus trastuzumab in combination with standard neoadjuvant anthracycline-containing and anthracycline-free chemotherapy regimens in patients with HER2-positive early breast cancer: a randomized phase II cardiac safety study (TRYPHAENA). Ann Oncol 24 (2013), 2278–2284.
54. 54 Hieken, T.J., Boughey, J.C., Jones, K.N., et al. Imaging response and residual metastatic axillary lymph node disease after neoadjuvant chemotherapy for primary breast cancer. Ann Surg Oncol 20 (2013), 3199–3204.
55. 55 Boughey, J.C., Ballman, K.V., Hunt, K.K., et al. Axillary ultrasound after neoadjuvant chemotherapy and its impact on sentinel lymph node surgery: results from the American College of Surgeons Oncology group Z1071 trial (Alliance). J Clin Oncol 33 (2015), 3386–3393.
56. 56 Klauber-Demore, N., Kuzmiak, C., Rager, E.L., et al. High-resolution axillary ultrasound is a poor prognostic test for determining pathologic lymph node status in patients undergoing neoadjuvant chemotherapy for locally advanced breast cancer. Am J Surg 188 (2004), 386–389.
57. 57 Shigekawa, T., Sugitani, I., Takeuchi, H., et al. Axillary ultrasound examination is useful for selecting patients optimally suited for sentinel lymph node biopsy after primary systemic chemotherapy. Am J Surg 204 (2012), 487–493.
58. 58 Cools-Lartigue, J., Meterissian, S., Accuracy of axillary ultrasound in the diagnosis of nodal metastasis in invasive breast cancer: a review. World J Surg 36 (2012), 46–54.
59. 59 Rousseau, C., Devillers, A., Campone, M., et al. FDG PET evaluation of early axillary lymph node response to neoadjuvant chemotherapy in stage II and III breast cancer patients. Eur J Nucl Med Mol Imaging 38 (2011), 1029–1036.
60. 60 Gil-Rendo, A., Zornoza, G., Garcia-Velloso, M.J., et al. Fluorodeoxyglucose positron emission tomography with sentinel lymph node biopsy for evaluation of axillary involvement in breast cancer. Br J Surg 93 (2006), 707–712.
61. 61 Greco, M., Crippa, F., Agresti, R., et al. Axillary lymph node staging in breast cancer by 2-fluoro-2-deoxy-D-glucose-positron emission tomography: clinical evaluation and alternative management. J Natl Cancer Inst 93 (2001), 630–635.
62. 62 Veronesi, U., De Cicco, C., Galimberti, V.E., et al. A comparative study on the value of FDG-PET and sentinel node biopsy to identify occult axillary metastases. Ann Oncol 18 (2007), 473–478.
63. 63 Wahl, R.L., Siegel, B.A., Coleman, R.E., et al., PET Study Group. Prospective multicenter study of axillary nodal staging by positron emission tomography in breast cancer: a report of the staging breast cancer with PET Study Group. J Clin Oncol 22 (2004), 277–285.
64. 64 Zornoza, G., Garcia-Velloso, M.J., Sola, J., et al. 18F-FDG PET complemented with sentinel lymph node biopsy in the detection of axillary involvement in breast cancer. Eur J Surg Oncol 30 (2004), 15–19.
65. 65 Cermik, T.F., Mavi, A., Basu, S., et al. Impact of FDG PET on the preoperative staging of newly diagnosed breast cancer. Eur J Nucl Med Mol Imaging 35 (2008), 475–483.
66. 66 Kim, J., Lee, J., Chang, E., et al. Selective sentinel node plus additional non-sentinel node biopsy based on an FDG-PET/CT scan in early breast cancer patients: single institutional experience. World J Surg 33 (2009), 943–949.
67. 67 Ueda, S., Tsuda, H., Asakawa, H., et al. Utility of 18F-fluoro-deoxyglucose emission tomography/computed tomography fusion imaging (18F-FDG PET/CT) in combination with ultrasonography for axillary staging in primary breast cancer. BMC Cancer, 8, 2008, 165.
68. 68 Hodgson, N.C., Gulenchyn, K.Y., Is there a role for positron emission tomography in breast cancer staging?. J Clin Oncol 26 (2008), 712–720.
69. 69 Noh, D.Y., Yun, I.J., Kim, J.S., et al. Diagnostic value of positron emission tomography for detecting breast cancer. World J Surg 22 (1998), 223–227 discussion 227–8.
70. 70 Chung, A., Liou, D., Karlan, S., et al. Preoperative FDG-PET for axillary metastases in patients with breast cancer. Arch Surg 141 (2006), 783–788 discussion 788–9.
71. 71 Fehr, M.K., Hornung, R., Varga, Z., et al. Axillary staging using positron emission tomography in breast cancer patients qualifying for sentinel lymph node biopsy. Breast J 10 (2004), 89–93.
72. 72 Javid, S., Segara, D., Lotfi, P., et al. Can breast MRI predict axillary lymph node metastasis in women undergoing neoadjuvant chemotherapy. Ann Surg Oncol 17 (2010), 1841–1846.
73. 73 Harada, T., Tanigawa, N., Matsuki, M., et al. Evaluation of lymph node metastases of breast cancer using ultrasmall superparamagnetic iron oxide-enhanced magnetic resonance imaging. Eur J Radiol 63 (2007), 401–407.
74. 74 Michel, S.C., Keller, T.M., Frohlich, J.M., et al. Preoperative breast cancer staging: MR imaging of the axilla with ultrasmall superparamagnetic iron oxide enhancement. Radiology 225 (2002), 527–536.
75. 75 Kimura, K., Tanigawa, N., Matsuki, M., et al. High-resolution MR lymphography using ultrasmall superparamagnetic iron oxide (USPIO) in the evaluation of axillary lymph nodes in patients with early stage breast cancer: preliminary results. Breast Cancer 17 (2010), 241–246.
76. 76 Schipper, R.J., Smidt, M.L., van Roozendaal, L.M., et al. Noninvasive nodal staging in patients with breast cancer using gadofosveset-enhanced magnetic resonance imaging: a feasibility study. Invest Radiol 48 (2013), 134–139.
77. 77 Bazan, J.G., White, J., Imaging of the axilla before preoperative chemotherapy: implications for postmastectomy radiation. Cancer 121 (2015), 1187–1194.
78. 78 Clarke, M., Collins, R., Darby, S., et al. Effects of radiotherapy and of differences in the extent of surgery for early breast cancer on local recurrence and 15-year survival: an overview of the randomised trials. Lancet 366 (2005), 2087–2106.
79. 79 Marks, L.B., Prosnitz, L.R., Reducing local therapy in patients responding to preoperative systemic therapy: are we outsmarting ourselves?. J Clin Oncol 32 (2014), 491–493.
80. 80 White, J., Mamounas, E., Locoregional radiotherapy in patients with breast cancer responding to neoadjuvant chemotherapy: a paradigm for treatment individualization. J Clin Oncol 32 (2014), 494–495.
81. 81 Liu, J., Mao, K., Jiang, S., et al. The role of postmastectomy radiotherapy in clinically node-positive, stage II-III breast cancer patients with pathological negative nodes after neoadjuvant chemotherapy: an analysis from the NCDB. Oncotarget 7 (2016), 24848–24859.
82. 82 Huang, E.H., Tucker, S.L., Strom, E.A., et al. Postmastectomy radiation improves local-regional control and survival for selected patients with locally advanced breast cancer treated with neoadjuvant chemotherapy and mastectomy. J Clin Oncol 22 (2004), 4691–4699.
83. 83 Wright, J.L., Takita, C., Reis, I.M., et al. Predictors of locoregional outcome in patients receiving neoadjuvant therapy and postmastectomy radiation. Cancer 119 (2013), 16–25.
84. 84 Community Oncology Research Program, NCI. CTSU Alliance A011202: A Randomized Phase III Trial Evaluating the Role of Axillary Lymph Node Dissection in Breast Cancer Patients (CT1–3N1) Who Have Positive Sentinel Lymph Node Disease after Neoadjuvant Chemotherapy. [Internet], 2014 [cited 1st January 2016]. Available at: http://www.kccop.org/cancer-trials/breast/index.cgi/summary?tID=110 Accessed April 1, 2016.
85. 85 Mamounas, E.P., White, J.R., Bandos, H., et al. NSABP B-51/RTOG 1304: randomized phase III clinical trial evaluating the role of postmastectomy chest wall and regional nodal XRT (CWRNRT) and post-lumpectomy RNRT in patients (pts) with documented positive axillary (Ax) nodes before neoadjuvant chemotherapy (NC) who convert to pathologically negative Ax nodes after NC [abstract]. J Clin Oncol, 32(5s), 2014 (suppl;abstr TPS1141).
86. 86 Alvarez, S., Añorbe, E., Alcorta, P., et al. Role of sonography in the diagnosis of axillary lymph node metastases in breast cancer: a systematic review. AJR Am J Roentgenol 186 (2006), 1342–1348.
87. 87 Jankowski, C., Hudry, D., Vaillant, D., et al. Evaluation of axillary involvement by ultrasound-guided lymph node biopsy: a prospective study. Gynecol Obstet Fertil 43 (2015), 431–436.
88. 88 Koolen, B.B., Valdés Olmos, R.A., Elkhuizen, P.H., et al. Locoregional lymph node involvement on 18F-FDG PET/CT in breast cancer patients scheduled for neoadjuvant chemotherapy. Breast Cancer Res Treat 135 (2012), 231–240.